Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice

• Published in: Microbiology spectrum 2022-06, Vol.10 (3), p.e0064722
• Main Authors: Sun, Xuewei, Cui, Qian, Ni, Juan, Liu, Xiaoguang, Zhu, Jin, Zhou, Tingting, Huang, HuaYing, OuYang, Ke, Wu, Yulong, Yang, Zhan
• Format: Article
• Language: English
• Subjects: acetaminophen; Acetaminophen - adverse effects; acute liver injury; Animals; Chemical and Drug Induced Liver Injury - drug therapy; Gastrointestinal Microbiome; gut microbiota; Host-Microbial Interactions; Liver; Male; Mice; Mice, Inbred C57BL; Research Article; TLR4
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.00647-22

Acetaminophen (APAP) overdose is one of the most common causes of acute liver injury (ALI) in Western countries. Many studies show that the gut microbiota plays an important role in liver injury. Currently, the only approved treatment for APAP-induced ALI is -acetylcysteine; therefore, it is essential to develop new therapeutic agents and explore the underlying mechanisms. We developed a novel monoclonal anti-Toll-like receptor 4 (TLR4) antibody (ATAB) and hypothesized that it has therapeutic effects on APAP-induced ALI and that gut microbiota may be involved in the underlying mechanism of ATAB treatment. Male C57BL/6 mice were treated with APAP and ATAB, which produced a therapeutic effect on ALI and altered the gut microbiota and their metabolic pathway, such as , , , and the fatty acid pathway, etc. Furthermore, we verified that purified short-chain fatty acids (SCFAs) could alleviate ALI. Moreover, a separate group of mice that received feces from the ATAB group showed less severe liver injury compared with the mice receiving feces from the APAP group. ATAB therapy also improved the gut barrier functions in mice and reduced the expression of protein zonulin. Our results revealed that gut microbiota plays an important role in the therapeutic effect of ATAB on APAP-induced ALI. In this study, we found the monoclonal anti-Toll-like receptor 4 antibody can alleviate APAP-induced acute liver injury through the change of the gut microbiota, metabolic pathways, and gut barrier function. This work suggested the gut microbiota can be the therapeutic target of the APAP-induced acute liver injury, and we performed the fundamental research for further research.